<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials during epidemics are initiated as a rapid response to public health emergency when there is limited information about clinical outcomes making estimation of sample size difficult. In the LOTUS China trial, the initial sample size was 160, assuming that the median time in the standard-care group was 20 days, and difference in median time to clinical improvement would be 8 days, and 75% of the patients would reach a clinical improvement.[
 <xref rid="ref1" ref-type="bibr">1</xref>] When planned enrollment of 160 patients was completed, the investigators realized that the trial was underpowered and decided to continue enrollment.[
 <xref rid="ref1" ref-type="bibr">1</xref>]
</p>
